The new rules, which cover both TV and radio, instruct drugmakers to use simple, consumer-friendly language when describing ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.

The U.S. Food and Drug Administration ( FDA) now requires TV and radio drug ads to be clearer and more direct. The new ...

Researchers at Ayass Bioscience have discovered and developed AYA22A aptamers, molecular compounds that target and bind to ...

The FDA has proposed ending the use of a common ingredient found in many cold and allergy medicines — and some pharmacies ...